Wir sind mit live! Mehr erfahren

Chimerix, Inc.

CMRX

Börsenwert 801 Mio. $

Nicht mehr börsennotiert

CMRX wurde am 17. April 2025 von der Börse genommen.

Zurück zu den Rankings

Profil: Chimerix Inc. is a biopharmaceutical company based in the United States that engages in the research, development, and commercialization of medicines. Its portfolio includes treatment for acute myeloid leukemia (or AML) and antiviral treatment for smallpox. The company generates revenue through revenue related to non-refundable upfront fees, royalties and milestone payments earned under license agreements, also by royalty revenue related to sales of TEMBEXA made by Emergent after the Asset Sale. The company operates only in one business segment namely pharmaceuticals.

Mitarbeiter: 81

Gesundheitswesen Arzneimittelhersteller – allgemein

Nachrichten

Positiv

Neutral

Negativ

Stimmung 3 Monate

Positiv 0 %

Neutral 0 %

Negativ 0 %

Top 3 Health Care Stocks That May Crash In Q2

As of April 7, 2025, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.

Top 3 Health Care Stocks That May Crash In Q2

Biotech Stocks Q1 2025 Recap: Winners And Underperformers

Investing in biotech can be highly rewarding but is fraught with risks; understanding past catalysts can help investors make informed decisions and minimize downside risk. CervoMed Inc. surged over 300% in Q1 2025 due to positive Phase 2b trial results for its lead drug candidate, neflamapimod despite earlier setbacks. Chimerix Inc. gained over 144% after announcing an acquisition by Jazz Pharmaceuticals and positive FDA feedback on its lead drug candidate, dordaviprone.

Biotech Stocks Q1 2025 Recap: Winners And Underperformers

Chimerix Reports Fourth Quarter and Year End 2024 Financial Results

New Drug Application (NDA) for Dordaviprone as Treatment for Recurrent H3 K27M-Mutant Diffuse Glioma Under Review with Prescription Drug User Fee Act (PDUFA) Action Date of August 18, 2025

Chimerix Reports Fourth Quarter and Year End 2024 Financial Results

CHIMERIX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Chimerix, Inc. - CMRX

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Chimerix, Inc. (NasdaqGM: CMRX) to Jazz Pharmaceuticals plc. (NasdaqGS: JAZZ). Under the terms of the proposed transaction, shareholders of Chimerix will receive $8.55 in cash for each share of Chimerix that they own. KSF is seeking to determine whether this consideration and the process that led to.

CHIMERIX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Chimerix, Inc. - CMRX

Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

DURHAM, N.C., March 07, 2025 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), today announced that on March 2, 2025, the Compensation Committee of Chimerix's Board of Directors granted an inducement award to a new employee of non-statutory stock options to purchase up to a total of 70,000 shares of Chimerix's common stock. The Compensation Committee of Chimerix's Board of Directors approved the award as an inducement material to the new employee's employment in accordance with Nasdaq Listing rule 5635(c)(4).

Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CMRX Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Chimerix, Inc. is Fair to Shareholders

NEW YORK, March 07, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Chimerix, Inc. (NASDAQ: CMRX) to Jazz Pharmaceuticals plc for $8.55 per share in cash is fair to Chimerix shareholders.

CMRX Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Chimerix, Inc. is Fair to Shareholders

Zacks Investment Research

The Zacks Analyst Blog Jazz Pharmaceuticals, Chimerix, Moderna, GSK and Regeneron Pharmaceuticals

Jazz Pharmaceuticals, Chimerix, Moderna, GSK and Regeneron Pharmaceuticals are included in this Analyst Blog.

The Zacks Analyst Blog Jazz Pharmaceuticals, Chimerix, Moderna, GSK and Regeneron Pharmaceuticals

Zacks Investment Research

Biotech Stocks Roundup: CMRX Up on JAZZ Bid, MRNA Up on Updates & More

CMRX and JAZZ are in the spotlight this week following an acquisition agreement.

Biotech Stocks Roundup: CMRX Up on JAZZ Bid, MRNA Up on Updates & More

Zacks Investment Research

Jazz Offers to Buy Chimerix for $935M to Boost Oncology Portfolio

JAZZ's acquisition of CMRX is set to add a rare high-grade brain tumor drug currently under the FDA's review. The deal is likely to be closed by June 2024.

Jazz Offers to Buy Chimerix for $935M to Boost Oncology Portfolio

$HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Chimerix, Inc. - CMRX

NEW YORK , March 5, 2025 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm by ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating Chimerix, Inc. (NASDAQ: CMRX ), relating to the proposed merger with Jazz Pharmaceuticals.

$HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Chimerix, Inc. - CMRX

Nachrichtenrankings ansehen

Kursdiagramme mit Lightweight Charts™ umgesetzt